MétaCan
Menu
Back to cohort
Record W4412491004 · doi:10.1186/s41181-025-00367-2

Auger electron-emitting EGFR-targeted and non-targeted [197Hg]Hg-gold nanoparticles for treatment of glioblastoma multiforme (GBM)

2025· article· en· W4412491004 on OpenAlexafffund
Madeline K. Brown, Zhongli Cai, Constantine J. Georgiou, Shaohuang Chen, Yumeela Ganga-Sah, Valery Radchenko, James T. Rutka, Raymond M. Reilly

Bibliographic record

VenueEJNMMI Radiopharmacy and Chemistry · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsHospital for Sick ChildrenUniversity of British ColumbiaPrincess Margaret Cancer CentreSimon Fraser UniversityTRIUMFUniversity of Toronto
FundersLeslie Dan Faculty of Pharmacy, University of TorontoNational Research Council CanadaNatural Sciences and Engineering Research Council of CanadaUniversity of TorontoCanadian Cancer SocietyCanadian Institutes of Health ResearchPfizer CanadaGovernment of Ontario
KeywordsChemistryPanitumumabColloidal goldIn vivoBiodistributionMolecular biologyCancer researchRadiochemistryIn vitroNanoparticleNanotechnologyMedicineMaterials scienceBiochemistryBiology

Abstract

fetched live from OpenAlex

Abstract Background We describe here radiation nanomedicines for glioblastoma multiforme (GBM) composed of gold nanoparticles (AuNPs) that integrate the Auger electron-emitter, 197Hg. [197Hg]Hg-AuNPs were conjugated to anti-epidermal growth factor receptor (EGFR) panitumumab or were non-targeted. Our aim was to compare the cytotoxicity and DNA-damaging properties in vitro of panitumumab-[197Hg]Hg-AuNPs and non-targeted [197Hg]Hg-AuNPs on U251-Luc human GBM cells and estimate their cellular dosimetry. We further aimed to compare the biodistribution in vivo of panitumumab-[197Hg]Hg-AuNPs and [197Hg]Hg-AuNPs after convection-enhanced delivery (CED) in NRG mice with U251-Luc tumours in the brain and estimate the absorbed doses in the tumour and surrounding margins of healthy brain. Results [197Hg]Hg-AuNPs (26.8 ± 6.4 nm) were produced with a radiochemical yield of 98 ± 1% by incorporating 197Hg into the Turkevich synthesis method, forming a mercury-gold amalgam. Panitumumab-[197Hg]Hg-AuNPs exhibited high affinity (KD = 1.8 × 10–9 mol/L) binding to EGFR-positive U251-Luc cells. The binding of panitumumab-[197Hg]Hg-AuNPs to U251-Luc cells was 15-fold higher than [197Hg]Hg-AuNPs, and internalization and nuclear uptake were 12-fold and 18-fold greater, respectively. Panitumumab-[197Hg]Hg-AuNPs caused 84-fold more DNA double-strand breaks (DSBs) in U251-Luc cells than [197Hg]Hg-AuNPs. Panitumumab-[197Hg]Hg-AuNPs were ninefold more effective at reducing the clonogenic survival of U251-Luc cells than [197Hg]Hg-AuNPs. Panitumumab-[197Hg]Hg-AuNPs were twofold more cytotoxic than non-radioactive panitumumab-AuNPs (P = 0.04) and fivefold more cytotoxic than panitumumab (P = 0.01). The absorbed doses in the nucleus of U251-Luc cells treated in vitro with panitumumab-[197Hg]Hg-AuNPs or [197Hg]Hg-AuNPs were 8.8 ± 2.9 Gy and 0.6 ± 0.1 Gy, respectively. SPECT/CT imaging showed that panitumumab-[197Hg]Hg-AuNPs and [197Hg]Hg-AuNPs were strongly retained at the infusion site in the brain after CED up to 7 d in NRG mice with orthotopic U251-Luc tumours. Uptake of panitumumab-[197Hg]Hg-AuNPs in the tumour-bearing right hemisphere [484.5% injected dose/g (%ID/g)] was 172-fold and 579-fold greater than in the healthy left hemisphere and cerebellum, respectively. The uptake of [197Hg]Hg-AuNPs (423.9% ID/g) in the tumour-bearing right hemisphere was 85-fold and 64-fold higher than the left hemisphere and cerebellum, respectively. Most normal tissue uptake was < 1% ID/g, except for kidneys (9–20% ID/g), spleen (3.5–6.6% ID/g) and liver (0.6–3.3% ID/g). Dosimetry showed that 58% of the tumour received > 190 Gy for CED of 1.0 MBq of panitumumab-[197Hg]Hg-AuNPs vs. 0.6% of the tumour for non-targeted [197Hg]Hg-AuNPs, but both agents deposited > 50 Gy in 95% of the tumour. Doses decreased dramatically to 1.7 and 3.3 Gy at 1–3 mm from the tumour edge for panitumumab-[197Hg]Hg-AuNPs and [197Hg]Hg-AuNPs, respectively. Conclusion Radiation nanomedicines incorporating the AE-emitter, 197Hg administered by CED are a promising approach to treatment of GBM. Panitumumab-[197Hg]Hg-AuNPs are particularly attractive due to their EGFR-mediated binding, internalization and nuclear importation in GBM cells, which amplifies their in vitro cytotoxicity.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.002

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.279
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueEJNMMI Radiopharmacy and ChemistrySame topicGlioma Diagnosis and TreatmentFrench-language works237,207